Published in World J Gastroenterol on February 14, 2007
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2010) 2.28
Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology (2008) 1.76
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J Gastroenterol (2007) 1.22
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22
Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol (2012) 1.07
Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res (2013) 1.03
Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol (2014) 1.00
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX. Liver Int (2013) 0.90
Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol (2013) 0.87
Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers. PLoS One (2014) 0.86
Serum cytokeratin 18 and cytokine elevations suggest a high prevalence of occupational liver disease in highly exposed elastomer/polymer workers. J Occup Environ Med (2011) 0.84
Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther (2011) 0.84
Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol (2009) 0.84
Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology (2013) 0.83
M-30 and 4HNE are sequestered in different aggresomes in the same hepatocytes. Exp Mol Pathol (2007) 0.82
Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One (2013) 0.82
Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci (2008) 0.82
Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol (2014) 0.81
Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. Int J Clin Exp Med (2014) 0.81
Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients. J Nutr Metab (2011) 0.81
Keratin 18 phosphorylation as a progression marker of chronic hepatitis B. Virol J (2010) 0.80
Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study. BMC Gastroenterol (2008) 0.80
A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World J Gastroenterol (2013) 0.79
Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.78
Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep (2015) 0.78
Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. PLoS One (2014) 0.78
Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci (2015) 0.77
Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol (2016) 0.77
Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol (2014) 0.76
Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci (2015) 0.76
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism (2016) 0.75
The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. PLoS One (2016) 0.75
Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev (2011) 0.75
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomed Res Int (2017) 0.75
Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int J Obes (Lond) (2017) 0.75
New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Intern Med (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 6.62
Nonalcoholic steatohepatitis. Ann Intern Med (1997) 5.74
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol (1999) 3.28
Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology (2003) 3.21
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Nonalcoholic steatohepatitis. Semin Liver Dis (2004) 2.89
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol (1997) 2.64
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology (2004) 2.41
Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med (1989) 2.28
Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology (1996) 2.23
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology (2004) 2.18
The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol (1999) 2.18
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res (2004) 2.03
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Apoptosis generates stable fragments of human type I keratins. J Biol Chem (1997) 1.72
Appropriateness of liver biopsy. Can J Gastroenterol (2000) 1.65
Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol (2000) 1.43
Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer (2003) 1.24
Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis (2001) 1.10
Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother (2005) 1.00
Apoptosis and fibrosis in non-alcoholic fatty liver disease. Turk J Gastroenterol (2005) 0.85
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology (2009) 1.48
Mobile phone exposure does not induce apoptosis on spermatogenesis in rats. Arch Med Res (2007) 1.43
The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer (2007) 1.11
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (2014) 1.02
The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct (2008) 1.02
Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn (2010) 1.00
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol (2003) 0.99
[Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains]. Mikrobiyol Bul (2009) 0.99
Combination of fenretinide and indole-3-carbinol results in synergistic cytotoxic activity inducing apoptosis against human breast cancer cells in vitro. Anticancer Drugs (2013) 0.96
Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol (2007) 0.96
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int (2009) 0.96
Effects of extremely low-frequency magnetic field on caspase activities and oxidative stress values in rat brain. Biol Trace Elem Res (2010) 0.95
Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration (2006) 0.94
Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food (2010) 0.94
Laparoscopic splenectomy and LigaSure. Surg Laparosc Endosc Percutan Tech (2005) 0.93
A case of torsion of the wandering spleen presenting as hypersplenism and gastric fundal varices. Turk J Gastroenterol (2011) 0.93
Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem (2010) 0.92
Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. Maturitas (2005) 0.92
Lumbar spinal extradural angiolipomas. Two case reports. Neurol Med Chir (Tokyo) (2006) 0.90
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol (2012) 0.90
Comparison of lateral and superior walls of the pituitary fossa with clinical emphasis on pituitary adenoma extension: cadaveric-anatomic study. Neurosurg Rev (2007) 0.89
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther (2011) 0.89
The relation between liver histopathology and GGT levels in viral hepatitis: more important in hepatitis B. Turk J Gastroenterol (2014) 0.87
Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest (2011) 0.87
Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit (2009) 0.87
Screening for hemochromatosis in Turkey. Dig Dis Sci (2004) 0.87
Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest (2010) 0.86
Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology (2009) 0.86
Palladium(II) saccharinate complexes with bis(2-pyridylmethyl)amine induce cell death by apoptosis in human breast cancer cells in vitro. Bioorg Med Chem (2013) 0.86
Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem (2009) 0.85
Single-agent irinotecan as second-line treatment for advanced gastric cancer. Tumori (2003) 0.85
Comparison of fragmented QRS and myocardial perfusion-gated SPECT findings. Nucl Med Commun (2013) 0.84
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother (2007) 0.83
Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol (2007) 0.82
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol (2009) 0.82
Apoptosis-inducing effects of Morinda citrifolia L. and doxorubicin on the Ehrlich ascites tumor in Balb-c mice. Cell Biochem Funct (2009) 0.82
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int (2015) 0.82
Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol (2009) 0.81
Metacarpal brown tumor in secondary hyperparathyroidism due to vitamin-D deficiency. A case report. J Bone Joint Surg Am (2005) 0.81
Effect of mobile phone exposure on apoptotic glial cells and status of oxidative stress in rat brain. Electromagn Biol Med (2009) 0.81
Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients. World J Gastroenterol (2007) 0.81
Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model? Fertil Steril (2007) 0.81
Investigation of fecal pancreatic elastase-1 levels in type 2 diabetic patients. Turk J Gastroenterol (2005) 0.81
Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. Eur J Gastroenterol Hepatol (2010) 0.81
Higher serum nitrate levels are associated with poor survival in lung cancer patients. Clin Biochem (2006) 0.81
Synthesis, structural characterization and cell death-inducing effect of novel palladium(II) and platinum(II) saccharinate complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine on cancer cells in vitro. Bioorg Med Chem (2013) 0.80
Can safe and long-term exposure to extremely low frequency (50 Hz) magnetic fields affect apoptosis, reproduction, and oxidative stress? Int J Radiat Biol (2013) 0.80
Lack of prognostic significance of SOCS-1 expression in colorectal adenocarcinomas. Asian Pac J Cancer Prev (2014) 0.80
Fas antigen (CD95) expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol (2003) 0.80
Lymphocyte subsets and cytokines in ascitic fluid of decompensated cirrhotic patients with and without spontaneous ascites infection. J Gastroenterol Hepatol (2006) 0.80
Colitis cystica profunda. Turk J Gastroenterol (2007) 0.80
Genotoxic, cytotoxic, and apoptotic effects of Hypogymnia physodes (L.) Nyl. on breast cancer cells. Environ Toxicol (2012) 0.80
Anatomy of the floor of the third ventricle in relation to endoscopic ventriculostomy. Clin Anat (2009) 0.80
AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J Gastroenterol Hepatol (2015) 0.80
Treatment of advanced classic Kaposi's sarcoma with weekly low-dose paclitaxel therapy. Int J Dermatol (2006) 0.79
A "biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. Obes Surg (2008) 0.79
Do liver IL-12 levels predict sustained response to IFN-alpha therapy in children with chronic hepatitis B? J Interferon Cytokine Res (2010) 0.79
Analysis of the outcomes of cardiopulmonary resuscitation in an emergency department. Acta Cardiol (2005) 0.79
Cytotoxic activity of novel palladium-based compounds on leukemia cell lines. Anticancer Drugs (2015) 0.79
Promising anti-growth effects of palladium(II) saccharinate complex of terpyridine by inducing apoptosis on transformed fibroblasts in vitro. Bioorg Med Chem (2013) 0.78
Anti-inflammatory efficiency of levobupivacaine in an experimental colitis model. World J Gastroenterol (2010) 0.78
IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis. Tumour Biol (2015) 0.78